---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-026864"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:34:05.722736+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology completes acquisition by Concentra Biosciences, shares delisted

## Summary
- Concentra Biosciences acquires Elevation Oncology for $0.36 per share plus contingent value right (CVR).
- 67.09% of shares tendered in the offer, satisfying the Minimum Tender Condition.
- All directors resign at closing; Kevin Tang becomes sole director of the surviving corporation.
- CEO/CFO Tammy Furlong terminated without cause, receives 12 months salary plus $600,000 lump sum.
- Company requests delisting from Nasdaq and deregistration under Exchange Act.

## SEC filing metadata
- accession: 0001140361-25-026864
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/ef20052364_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-026864
- JSON: https://secwatch.observer/filing/0001140361-25-026864.json
- Plain text: https://secwatch.observer/filing/0001140361-25-026864.txt

## Key facts
- Governance Changes
  Elevation Oncology, Inc.: Amended and restated bylaws in their entirety.
  - Change: bylaw amendment
  source text: the Company’s certificate of incorporation and bylaws were amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm
- Governance Changes
  Elevation Oncology, Inc.: Amended and restated certificate of incorporation in its entirety.
  - Change: charter amendment
  source text: the Company’s certificate of incorporation and bylaws were amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm
- M&A Transactions
  Elevation Oncology, Inc. completed an acquisition involving Concentra Merger Sub VI, Inc. (a wholly owned subsidiary of Concentra Biosciences, LLC) for $0.36 per share plus one contingent value right (CVR) per share (closed 2025-07-23).
  - Action: acquisition
  - Counterparty: Concentra Merger Sub VI, Inc. (a wholly owned subsidiary of Concentra Biosciences, LLC)
  - Consideration: $0.36 per share plus one contingent value right (CVR) per share
  - Closing: 2025-07-23
  source text: Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on July 23, 2025, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ” and shares of Common Stock, “ Shares ”), in exchange for (i) $0.36 in cash per Share (the “Cash Amount”); plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR,” and each CVR together with the Cash Amount, the “ Offer Price ”), which CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the contingent value rights agreement (the “ CVR Agreement ”), dated July 23, 2025, by and among Concentra, Merger Sub, Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, and Fortis Advisors LLC, a Delaware limited liability company, all subject to and in accordance with the terms and conditions set forth in the Offer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000114036125026864/0001140361-25-026864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.